Refereed Journals


[244] Structure Elaboration of Isoniazid: Synthesis, in silico Molecular Docking and Antimycobacterial Activity of Isoniazid-Pyrimidine Conjugates H. Kaur, L. Singh, K. Chibale and K. Singh* Molecular Diversity., 2019
[243] Design and synthesis of novel ferrocene-quinoline conjugates and evaluation of their electrochemical and antiplasmodium properties.  A.Minić,* T. Van de Walle, K. Van Hecke, J. Combrinck, P. J. Smith, K. Chibale, and Matthias D'hooghe ∗ Eur. J. Med. Chem, 2019, 187, 111963
[242] Synthesis, In Silico Molecular Docking, ADME Evaluation and In Vitro Antiplasmodial Activity of Pyrimidine-Based Hybrid Molecules.  R. Chopra, L. Singh, K. Chibale, and K. Singh* ChemistrySelect., 2019, 4 (43), 12556-12558
[241] Exploring the Anti-Plasmodial 2-Aminopyridines as Potential Anti-Trypanosomal agents.  C.G.L. Veale,* D. Lamming, T. Swart, K.  Chibale, H.C. Hoppe ChemMedChem 2019, 14, 2034–2041
[240] Semisynthetic Antimycobacterial C-3 Silicate and C-3/ C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma and Mycobacterium tuberculosis culture. M. Njoroge, G. Kaur, M. Espinoza-Moraga, A. Wasuna, G. Dziwornu, R. Seldon, D. Taylor, J. Okombo, D. Warner and K. Chibale* ACS Infect. Dis. 2019, 5, 1634−1644
[239] Azaaurones as potent antimycobacterial agents active against MDR- and XDR-TB. A. Campaniço, M. Carrasco, M. Njoroge, K. Chibale, J. Perdigão, I. Portugal, R. Moreira, D. Warner, F. Lopes*, ChemMedChem., 2019,14, 1537 - 1546
[238]  Five Solid Forms of a Potent Imidazopyridazine Antimalarial Drug Lead: A Preformulation Study. T. J. Noonan, K. Chibale, P. M. Cheuka, M. Kumar, S. A. Bourne, M. R. Caira* Crystal Growth & Design. 2019, 19 (8), 4683−4697
[237] Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insights.  N. Baartzes, T. Stringer, R. Seldon, D.F. Warner, D. Taylor, S. Wittlin
K. Chibale and G. S. Smith∗ Eur. J. Med. Chem, 2019, 161, 11–21
{236] Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: Synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin.  G. A. Dziwornu, S. Kamunya, T. Ntsabo, and K. Chibale*. MedChemComm, 2019, 10, 961 - 969
[235] Co-crystal and salt forms of an imidazopyridazine antimalarial drug lead. T. J. Noonan, K. Chibale, P.M. Cheuka, S.A. Bourne, M.R. Caira*. Journal of Pharmaceutical Sciences 2019, 108, 2349-2357
[234] Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.  J. D. Paccez, K. Duncan, D. Sekar, R.G. Correa3, Y. Wang, X. Gu, M. Bashin, K. Chibale, T. A. Libermann and L.F. Zerbini*. Oncogenesis (2019) 8:14 or Oncogenesis 2019, 8, 1−14
[233] Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles.  H.D. Attram, S. Wittlin and K. Chibale*. Med. Chem. Commun., 2019, 10, 450 −455
[232] Structure−Activity Relationship and in Vitro Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Studies of N‑aryl 3‑Trifluoromethyl Pyrido[1,2‑a]benzimidazoles that Are Efficacious in a Mouse Model of Schistosomiasis.  G. Mayoka, J. Keiser, C. Häberli and K. Chibale* ACS Infect. Dis. 2019, 5, 418−429
[231] Antimalarial Pyrido[1,2‑a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies.   J. Okombo, and K. Chibale* ACS Infect. Dis. 2019, 5, 372−384
[230] Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action.  M. Kumar, J. Okombo, D. Mambwe, D. Taylor, N. Lawrence, J. Reader, M. van der Watt, D. Fontinha, M. Sanches-Vaz, B. C. Bezuidenhout, S. B Lauterbach, D. Liebenberg, L.-M. Birkholtz, T.L. Coetzer, M. Prudêncio, T. J. Egan, S. Wittlin and K. Chibale* ACS Infect. Dis. 2019, 5, 303−315
[229] Structure−Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N‑Aryl-3-trifluoromethyl Pyrido[1,2‑a]benzimidazoles Which Are Efficacious in an in Vivo
Mouse Model of Malaria.  G. Mayoka, M. Njoroge, J. Okombo, L. Gibhard, M. Sanches-Vaz, D. Fontinha,L.-M. Birkholtz, J. Reader, M. van der Watt, T. L. Coetzer, S. Lauterbach, A. Churchyard, B. Bezuidenhout, T. J. Egan, C.Yeates, S. Wittlin, M. Prudêncio, and K. Chibale* J. Med. Chem. 2019, 62, 1022−1035
[228] Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles.  L. Rylands, A. Welsh, K. Maepa, T. Stringer, D. Taylor, K. Chibale and G. S. Smith∗ Eur. J. Med. Chem, 2019, 161, 11–21